Table 1 Baseline patient characteristics
|  | Exemestane Arm (N = 221) | Sequential Arm (N = 212) | Total (N = 433) | Dutch population in TEAM trial analysis (N = 2754)a | P value (current study vs. Dutch population in the TEAM trial)b |
|---|---|---|---|---|---|
Age | |||||
 Median [Min, Max] | 65.0 [46.0, 85.0] | 64.5 [46.0, 90.0] | 65.0 [46.0, 90.0] | 64.0 [38.0, 96.0] | 0.694 |
Tumor stage | |||||
 pT1 | 100 (45.2%) | 94 (44.3%) | 194 (44.8%) | 1236 (44.9%) | 0.423 |
 pT2 | 112 (50.7%) | 110 (51.9%) | 222 (51.3%) | 1329 (48.3%) |  |
 pT3 | 5 (2.3%) | 3 (1.4%) | 8 (1.8%) | 120 (4.4%) |  |
 pT4 | 4 (1.8%) | 5 (2.4%) | 9 (2.1%) | 63 (2.3%) |  |
Lymph node stage | |||||
 pN0 | 71 (32.1%) | 66 (31.1%) | 137 (31.6%) | 832 (30.2%) | 0.085 |
 pN1 | 139 (62.9%) | 128 (60.3%) | 267 (61.7%) | 1454 (52.8%) |  |
 pN2 | 11 (5.0%) | 18 (8.5%) | 29 (6.7%) | 327 (11.9%) |  |
TNM stage | |||||
 I | 30 (13.6%) | 22 (10.4%) | 52 (12.0%) | 354 (12.9%) | 0.208 |
 IIA | 102 (46.2%) | 105 (49.5%) | 207 (47.8%) | 1183 (43.0%) |  |
 IIB | 74 (33.5%) | 63 (29.7%) | 137 (31.6%) | 661 (24.0%) |  |
 IIIA | 11 (5.0%) | 17 (8.0%) | 28 (6.5%) | 352 (12.8%) |  |
 IIIB | 4 (1.8%) | 5 (2.4%) | 9 (2.1%) | 53 (1.9%) |  |
Histological grade | |||||
 G1 | 40 (18.1%) | 49 (23.1%) | 89 (20.6%) | 420 (15.3%) | < 0.001 |
 G2 | 117 (52.9%) | 115 (54.2%) | 232 (53.6%) | 1219 (44.3%) |  |
 G3 | 64 (29.0%) | 48 (22.6%) | 112 (25.9%) | 934 (33.9%) |  |
Estrogen receptor (ER) | |||||
 Positive | 219 (99.1%) | 209 (98.6%) | 428 (98.8%) | 2700 (98.0%) | 0.335 |
 Negative | 2 (0.9%) | 3 (1.4%) | 5 (1.2%) | 53 (1.9%) |  |
Progesterone receptor (PR) | |||||
 Positive | 185 (83.7%) | 176 (83.0%) | 361 (83.4%) | 1999 (72.6%) | < 0.001 |
 Negative | 35 (15.8%) | 31 (14.6%) | 66 (15.2%) | 601 (21.8%) |  |
 Not determined | 1 (0.5%) | 5 (2.4%) | 6 (1.4%) | 153 (5.6%) |  |
Chemotherapy received | |||||
 Yes | 44 (19.9%) | 46 (21.7%) | 90 (20.8%) | 812 (29.5%) | < 0.001 |
 No | 177 (80.1%) | 166 (78.3%) | 343 (79.2%) | 1942 (70.5%) |  |